273 related articles for article (PubMed ID: 21724849)
1. Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein.
Tan J; Zhang T; Jiang L; Chi J; Hu D; Pan Q; Wang D; Zhang Z
J Biol Chem; 2011 Aug; 286(34):29654-62. PubMed ID: 21724849
[TBL] [Abstract][Full Text] [Related]
2. Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2.
Park JS; Sue CM
Curr Protein Pept Sci; 2017; 18(7):725-732. PubMed ID: 26965689
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism.
Park JS; Mehta P; Cooper AA; Veivers D; Heimbach A; Stiller B; Kubisch C; Fung VS; Krainc D; Mackay-Sim A; Sue CM
Hum Mutat; 2011 Aug; 32(8):956-64. PubMed ID: 21542062
[TBL] [Abstract][Full Text] [Related]
4. Common pathogenic effects of missense mutations in the P-type ATPase ATP13A2 (PARK9) associated with early-onset parkinsonism.
Podhajska A; Musso A; Trancikova A; Stafa K; Moser R; Sonnay S; Glauser L; Moore DJ
PLoS One; 2012; 7(6):e39942. PubMed ID: 22768177
[TBL] [Abstract][Full Text] [Related]
5. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9).
Daniel G; Musso A; Tsika E; Fiser A; Glauser L; Pletnikova O; Schneider BL; Moore DJ
Neurobiol Dis; 2015 Jan; 73():229-43. PubMed ID: 25461191
[TBL] [Abstract][Full Text] [Related]
6. ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome.
Grünewald A; Arns B; Seibler P; Rakovic A; Münchau A; Ramirez A; Sue CM; Klein C
Neurobiol Aging; 2012 Aug; 33(8):1843.e1-7. PubMed ID: 22296644
[TBL] [Abstract][Full Text] [Related]
7. Altered apoptosis regulation in Kufor-Rakeb syndrome patients with mutations in the ATP13A2 gene.
Radi E; Formichi P; Di Maio G; Battisti C; Federico A
J Cell Mol Med; 2012 Aug; 16(8):1916-23. PubMed ID: 22117566
[TBL] [Abstract][Full Text] [Related]
8. Mutant Atp13a2 proteins involved in parkinsonism are degraded by ER-associated degradation and sensitize cells to ER-stress induced cell death.
Ugolino J; Fang S; Kubisch C; Monteiro MJ
Hum Mol Genet; 2011 Sep; 20(18):3565-77. PubMed ID: 21665991
[TBL] [Abstract][Full Text] [Related]
9. Novel mutations in ATP13A2 associated with mixed neurological presentations and iron toxicity due to nonsense-mediated decay.
Kırımtay K; Temizci B; Gültekin M; Yapıcı Z; Karabay A
Brain Res; 2021 Jan; 1750():147167. PubMed ID: 33091395
[TBL] [Abstract][Full Text] [Related]
10. The Parkinson-associated human P5B-ATPase ATP13A2 modifies lipid homeostasis.
Marcos AL; Corradi GR; Mazzitelli LR; Casali CI; Fernández Tome MDC; Adamo HP; de Tezanos Pinto F
Biochim Biophys Acta Biomembr; 2019 Oct; 1861(10):182993. PubMed ID: 31132336
[TBL] [Abstract][Full Text] [Related]
11. ATP13A2/PARK9 regulates endo-/lysosomal cargo sorting and proteostasis through a novel PI(3, 5)P2-mediated scaffolding function.
Demirsoy S; Martin S; Motamedi S; van Veen S; Holemans T; Van den Haute C; Jordanova A; Baekelandt V; Vangheluwe P; Agostinis P
Hum Mol Genet; 2017 May; 26(9):1656-1669. PubMed ID: 28334751
[TBL] [Abstract][Full Text] [Related]
12. Loss of ATP13A2 impairs glycolytic function in Kufor-Rakeb syndrome patient-derived cell models.
Park JS; Koentjoro B; Davis RL; Sue CM
Parkinsonism Relat Disord; 2016 Jun; 27():67-73. PubMed ID: 27039055
[TBL] [Abstract][Full Text] [Related]
13. PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity.
Ramonet D; Podhajska A; Stafa K; Sonnay S; Trancikova A; Tsika E; Pletnikova O; Troncoso JC; Glauser L; Moore DJ
Hum Mol Genet; 2012 Apr; 21(8):1725-43. PubMed ID: 22186024
[TBL] [Abstract][Full Text] [Related]
14. Lysosomal Storage of Subunit c of Mitochondrial ATP Synthase in Brain-Specific Atp13a2-Deficient Mice.
Sato S; Koike M; Funayama M; Ezaki J; Fukuda T; Ueno T; Uchiyama Y; Hattori N
Am J Pathol; 2016 Dec; 186(12):3074-3082. PubMed ID: 27770614
[TBL] [Abstract][Full Text] [Related]
15. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9).
Eiberg H; Hansen L; Korbo L; Nielsen IM; Svenstrup K; Bech S; Pinborg LH; Friberg L; Hjermind LE; Olsen OR; Nielsen JE
Clin Genet; 2012 Sep; 82(3):256-63. PubMed ID: 21696388
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of human Atp13a2Isoform-1 protein protects cells against manganese and starvation-induced toxicity.
Ugolino J; Dziki KM; Kim A; Wu JJ; Vogel BE; Monteiro MJ
PLoS One; 2019; 14(8):e0220849. PubMed ID: 31393918
[TBL] [Abstract][Full Text] [Related]
17. Dysregulated iron metabolism in C. elegans catp-6/ATP13A2 mutant impairs mitochondrial function.
Anand N; Holcom A; Broussalian M; Schmidt M; Chinta SJ; Lithgow GJ; Andersen JK; Chamoli M
Neurobiol Dis; 2020 Jun; 139():104786. PubMed ID: 32032734
[TBL] [Abstract][Full Text] [Related]
18. Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove.
Dehay B; Martinez-Vicente M; Ramirez A; Perier C; Klein C; Vila M; Bezard E
Autophagy; 2012 Sep; 8(9):1389-91. PubMed ID: 22885599
[TBL] [Abstract][Full Text] [Related]
19. Loss-of-function mutations in the ATP13A2/PARK9 gene cause complicated hereditary spastic paraplegia (SPG78).
Estrada-Cuzcano A; Martin S; Chamova T; Synofzik M; Timmann D; Holemans T; Andreeva A; Reichbauer J; De Rycke R; Chang DI; van Veen S; Samuel J; Schöls L; Pöppel T; Mollerup Sørensen D; Asselbergh B; Klein C; Zuchner S; Jordanova A; Vangheluwe P; Tournev I; Schüle R
Brain; 2017 Feb; 140(2):287-305. PubMed ID: 28137957
[TBL] [Abstract][Full Text] [Related]
20. Kufor-Rakeb Syndrome/PARK9: One Novel and One Possible Recurring Ashkenazi ATP13A2 Mutation.
Inzelberg R; Estrada-Cuzcano A; Laitman Y; De Vriendt E; Friedman E; Jordanova A
J Parkinsons Dis; 2018; 8(3):399-403. PubMed ID: 29966207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
